C4 Therapeutics, Inc. Balance Sheet
CCCC|4 years of annual SEC 10-K data (FY2022-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
C4 Therapeutics, Inc. had $359M in total assets and $257M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash & Equivalents | $74.6M | $55.5M | $126.6M | $29.8M |
| Accounts Receivable | $2.4M | $3.1M | $11.8M | $1.5M |
| Current Assets | $258.1M | $257.8M | $271.2M | $287.6M |
| PP&E (Net) | $4.7M | $5.8M | $7.1M | $7.4M |
| Total Assets | $359.1M | $349.6M | $376.5M | $430.8M |
| Current Liabilities | $33.0M | $45.2M | $42.8M | $44.5M |
| Total Debt | - | - | $0 | $11.5M |
| Shareholders' Equity | $256.6M | $246.1M | $246.1M | $389.6M |